US5422105A
(en)
*
|
1985-02-05 |
1995-06-06 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor 1
|
US5573930A
(en)
*
|
1985-02-05 |
1996-11-12 |
Cetus Oncology Corporation |
DNA encoding various forms of colony stimulating factor-1
|
US5104650A
(en)
*
|
1985-02-05 |
1992-04-14 |
Cetus Corporation |
Uses of recombinant colony stimulating factor-1
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
US6146851A
(en)
*
|
1985-02-05 |
2000-11-14 |
Chiron Corporation |
DNA encoding NV2 (long form) and carboxy truncated fragments thereof
|
US6156300A
(en)
*
|
1985-02-05 |
2000-12-05 |
Chiron Corporation |
Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
|
US5650297A
(en)
*
|
1986-09-17 |
1997-07-22 |
Otsuka Pharmaceutical Co., Ltd. |
DNA encoding human colony-stimulating factors
|
US5084559A
(en)
*
|
1987-03-27 |
1992-01-28 |
Repligen Corporation |
Protein a domain mutants
|
US5153265A
(en)
*
|
1988-01-20 |
1992-10-06 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
JPH01193227A
(ja)
*
|
1988-01-29 |
1989-08-03 |
Res Dev Corp Of Japan |
癌免疫療法補助剤
|
US5322678A
(en)
*
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
GB8824591D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
US5349052A
(en)
*
|
1988-10-20 |
1994-09-20 |
Royal Free Hospital School Of Medicine |
Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
|
US5162430A
(en)
*
|
1988-11-21 |
1992-11-10 |
Collagen Corporation |
Collagen-polymer conjugates
|
US5264214A
(en)
*
|
1988-11-21 |
1993-11-23 |
Collagen Corporation |
Composition for bone repair
|
US5306500A
(en)
*
|
1988-11-21 |
1994-04-26 |
Collagen Corporation |
Method of augmenting tissue with collagen-polymer conjugates
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US5565519A
(en)
*
|
1988-11-21 |
1996-10-15 |
Collagen Corporation |
Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
|
JP2989002B2
(ja)
*
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US6225449B1
(en)
*
|
1991-10-04 |
2001-05-01 |
Washington University |
Hormone analogs with multiple CTP extensions
|
US5288487A
(en)
*
|
1989-02-28 |
1994-02-22 |
Morinaga Milk Industry Co., Ltd. |
Human monocyte-macrophage-CSF preparations
|
ATE300519T1
(de)
*
|
1989-04-19 |
2005-08-15 |
Enzon Inc |
Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
US7264944B1
(en)
*
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6207454B1
(en)
|
1989-10-16 |
2001-03-27 |
Amgen Inc. |
Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
|
US6204363B1
(en)
|
1989-10-16 |
2001-03-20 |
Amgen Inc. |
Stem cell factor
|
US7144731B2
(en)
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US6248319B1
(en)
|
1989-10-16 |
2001-06-19 |
Krisztina M. Zsebo |
Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
|
ATE194651T1
(de)
|
1989-10-16 |
2000-07-15 |
Amgen Inc |
Stammzellenfaktor
|
GEP20002145B
(en)
*
|
1989-10-16 |
2000-06-25 |
Amgen Inc Us |
Stem Cell Factor
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
WO1991006567A1
(en)
*
|
1989-11-07 |
1991-05-16 |
Otsuka Pharmaceutical Co., Ltd. |
M-csf derivative, expression vector of said derivative, product of transformation by said vector, and production of them
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
DK0458064T3
(da)
*
|
1990-05-04 |
1998-04-27 |
American Cyanamid Co |
Stabilisering af somatotropiner ved modificering af cysteinrester
|
US5951972A
(en)
*
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
JP3051145B2
(ja)
*
|
1990-08-28 |
2000-06-12 |
住友製薬株式会社 |
新規なポリエチレングリコール誘導体修飾ペプチド
|
US5219991A
(en)
*
|
1990-09-21 |
1993-06-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Macrophage stimulating protein
|
EP0575545B1
(de)
*
|
1991-03-15 |
2003-05-21 |
Amgen Inc. |
Pegylation von polypeptiden
|
JPH06506217A
(ja)
*
|
1991-03-18 |
1994-07-14 |
エンゾン,インコーポレーテッド |
ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
NZ244778A
(en)
*
|
1991-10-21 |
1994-03-25 |
Ortho Pharma Corp |
Peg imidates and protein derivatives thereof
|
JPH06506479A
(ja)
*
|
1991-11-25 |
1994-07-21 |
デイド、インターナショナル、インコーポレイテッド |
合成htlv−2ペプチドを用いるイムノアッセイ
|
IT1260468B
(it)
*
|
1992-01-29 |
1996-04-09 |
|
Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
|
FR2687681B1
(fr)
*
|
1992-02-20 |
1995-10-13 |
Transgene Sa |
Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
|
WO1994001483A1
(en)
*
|
1992-07-02 |
1994-01-20 |
Collagen Corporation |
Biocompatible polymer conjugates
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
WO1994005332A2
(en)
*
|
1992-09-01 |
1994-03-17 |
Berlex Laboratories, Inc. |
Glycolation of glycosylated macromolecules
|
NZ250375A
(en)
*
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
AU6400094A
(en)
*
|
1993-03-09 |
1994-09-26 |
Enzon, Inc. |
Taxol polyalkylene oxide conjugates of taxol and taxol intermediates
|
AU7097094A
(en)
*
|
1993-06-01 |
1994-12-20 |
Enzon, Inc. |
Carbohydrate-modified polymer conjugates with erythropoietic activity
|
IL110787A0
(en)
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
JPH09504033A
(ja)
*
|
1993-10-20 |
1997-04-22 |
エンゾン,インコーポレーテッド |
2’−及び/又は7−置換タキソイド類
|
US8147844B1
(en)
|
1994-01-03 |
2012-04-03 |
Genentech, Inc. |
Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand
|
US8241900B1
(en)
|
1994-01-03 |
2012-08-14 |
Genentech, Inc. |
mpl ligand
|
US8192955B1
(en)
*
|
1994-01-03 |
2012-06-05 |
Genentech, Inc. |
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
|
DE4404168A1
(de)
*
|
1994-02-10 |
1995-08-17 |
Hoechst Ag |
Hirudinderivate und Verfahren zu deren Herstellung
|
US8278099B1
(en)
|
1994-02-15 |
2012-10-02 |
Genentech, Inc. |
Monoclonal antibody to human thrombopoietin
|
WO1995026746A1
(en)
*
|
1994-03-31 |
1995-10-12 |
Amgen Inc. |
Compositions and methods for stimulating megakaryocyte growth and differentiation
|
US5795569A
(en)
*
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US7883693B2
(en)
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
US6833408B2
(en)
*
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
EP0876165B1
(de)
*
|
1995-12-18 |
2006-06-21 |
Angiotech BioMaterials Corp. |
Vernetzten polymerisatmassen und verfahren für ihre verwendung
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US6072040A
(en)
*
|
1996-10-15 |
2000-06-06 |
Medical Analysis Systems, Inc. |
Stabilized conjugates of uncomplexed subunits of multimeric proteins
|
DE69724451T2
(de)
|
1996-12-06 |
2004-03-18 |
Amgen Inc., Thousand Oaks |
Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
|
AU729062C
(en)
*
|
1997-01-14 |
2004-03-25 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptors 6alpha & 6beta
|
US20040013664A1
(en)
*
|
1997-01-14 |
2004-01-22 |
Gentz Reiner L. |
Tumor necrosis factor receptors 6 alpha & 6 beta
|
US7285267B2
(en)
|
1997-01-14 |
2007-10-23 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptors 6α & 6β
|
US5965704A
(en)
*
|
1997-08-05 |
1999-10-12 |
Zymogenetics, Inc. |
Class two cytokine receptor-11
|
US6391311B1
(en)
*
|
1998-03-17 |
2002-05-21 |
Genentech, Inc. |
Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
|
US6458355B1
(en)
*
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
*
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
US7371836B2
(en)
*
|
1998-03-27 |
2008-05-13 |
Genentech, Inc. |
PRO526 nucleic acids
|
DE69942834D1
(de)
|
1998-08-06 |
2010-11-18 |
Univ Duke |
Harnsäureoxidase
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
US20060188971A1
(en)
*
|
1998-08-06 |
2006-08-24 |
Duke University |
Urate oxidase
|
DK2316475T3
(da)
|
1998-08-06 |
2017-11-20 |
Mountain View Pharmaceuticals Inc |
Isoleret tetramer urikase
|
AU6027399A
(en)
*
|
1998-09-04 |
2000-03-27 |
Ludwig Institute For Cancer Research |
An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
|
EE04967B1
(et)
|
1998-10-16 |
2008-02-15 |
Biogen, Incorporated |
Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
MXPA01003790A
(es)
*
|
1998-10-16 |
2002-09-18 |
Biogen Inc |
Proteinas de fusion beta - interferon y sus usos.
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
EP1129193A4
(de)
*
|
1998-11-10 |
2005-08-10 |
Human Genome Sciences Inc |
Chemokin beta-7
|
DK1157037T3
(da)
*
|
1999-01-29 |
2003-11-24 |
Hoffmann La Roche |
GCSF-konjugater
|
US7270972B1
(en)
*
|
1999-04-02 |
2007-09-18 |
Ajinomoto Co., Inc. |
Process for producing subunit peptide originating in polymer protein
|
US20050079577A1
(en)
*
|
1999-05-14 |
2005-04-14 |
Ashkenazi Avi J. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
AU782580B2
(en)
|
2000-01-10 |
2005-08-11 |
Maxygen, Inc. |
G-CSF conjugates
|
DK1257295T3
(da)
|
2000-02-11 |
2009-08-10 |
Bayer Healthcare Llc |
Faktor VII eller VIIA-lignende molekyler
|
AR032757A1
(es)
*
|
2000-06-30 |
2003-11-26 |
Smithkline Beecham Corp |
Composiciones biologicamente activas de conjugados de quimioquina, uso de dichas composiciones en la fabricacion de composiciones farmaceuticas, metodo para preparar dichas composiciones, y metodos para mejorar la farmacocinetica de una quimioquina
|
EP1337636B1
(de)
*
|
2000-08-08 |
2006-10-18 |
ZymoGenetics, Inc. |
Lösliche zcyctor 11 cytokinrezeptoren
|
JP2004531694A
(ja)
*
|
2000-10-23 |
2004-10-14 |
ジェネティックス インスティテュート エルエルシー |
酸不安定同位体コード抽出剤(alice)及びタンパク質混合物の定量的マススペクトロメトリック分析におけるその使用
|
WO2002083063A2
(en)
*
|
2000-11-03 |
2002-10-24 |
Smithkline Beecham Corporation |
Method of improving systemic exposure of subcutaneously administered therapeutic proteins
|
EP1366075B1
(de)
|
2001-02-27 |
2009-05-27 |
Maxygen Aps |
Neue interferon-beta-ähnliche moleküle
|
DE10112825A1
(de)
*
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
JP4502580B2
(ja)
*
|
2001-05-16 |
2010-07-14 |
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド |
敗血症の治療または予防のためのil−18阻害剤の使用
|
US20020198139A1
(en)
*
|
2001-05-17 |
2002-12-26 |
Deutschman Clifford S. |
Method of preventing acute pulmonary cell injury
|
CN101724075B
(zh)
*
|
2001-10-10 |
2014-04-30 |
诺和诺德公司 |
肽的重构和糖缀合
|
US7157277B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7173003B2
(en)
*
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
DE10209821A1
(de)
*
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
DE10209822A1
(de)
*
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
BR0308710A
(pt)
*
|
2002-03-26 |
2007-01-09 |
Biosynexus Inc |
conjugados poliméricos antimicrobianos
|
JP2006507850A
(ja)
*
|
2002-03-26 |
2006-03-09 |
バイオシネクサス インコーポレイテッド |
細菌バイオフィルムの酵素破壊
|
MXPA04012496A
(es)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
CN101301475B
(zh)
|
2002-06-21 |
2012-12-19 |
诺和诺德医疗保健公司 |
Peg化因子vii糖型
|
AU2003270341A1
(en)
*
|
2002-09-05 |
2004-03-29 |
The General Hospital Corporation |
Modified asialo-interferons and uses thereof
|
EP1400533A1
(de)
*
|
2002-09-11 |
2004-03-24 |
Fresenius Kabi Deutschland GmbH |
Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
|
DE10242076A1
(de)
*
|
2002-09-11 |
2004-03-25 |
Fresenius Kabi Deutschland Gmbh |
HAS-Allergen-Konjugate
|
EP1681303B1
(de)
*
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylierte Polypeptide, besonders HASyliertes Erythropoietin
|
CN100348618C
(zh)
*
|
2002-09-11 |
2007-11-14 |
弗雷泽纽斯卡比德国有限公司 |
生产羟烷基淀粉衍生物的方法
|
WO2004026251A2
(en)
*
|
2002-09-20 |
2004-04-01 |
Pharmacia Corporation |
Process for decreasing aggregate levels of pegylated protein
|
AU2003273413A1
(en)
*
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
EA013535B1
(ru)
*
|
2002-12-26 |
2010-06-30 |
Маунтин Вью Фамэсьютикэлс, Инк. |
Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
|
EP1667708B9
(de)
|
2002-12-26 |
2012-10-31 |
Mountain View Pharmaceuticals, Inc. |
INTERFERON-BETA-1b POLYETHYLENEGLYKOL-KONJUGATE MIT ERHÖHTER IN VITRO BIOLOGISCHER WIRKSAMKEIT
|
JP2006516548A
(ja)
|
2002-12-30 |
2006-07-06 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
迅速ゲル化ポリマー組成物からの薬物送達法
|
AU2003303513A1
(en)
*
|
2002-12-30 |
2004-07-29 |
Angiotech International Ag |
Tissue reactive compounds and compositions and uses thereof
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
EA009124B1
(ru)
*
|
2003-03-24 |
2007-10-26 |
Займоджинетикс, Инк. |
Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении
|
US20100221237A1
(en)
*
|
2003-03-26 |
2010-09-02 |
Biosynexus Incorporated |
Enzyme disruption of bacterial biofilms
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
JP4753867B2
(ja)
|
2003-04-15 |
2011-08-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
ヒトil−18を含むコンジュゲートおよびその置換変異体
|
BRPI0410164A
(pt)
*
|
2003-05-09 |
2006-05-16 |
Neose Technologies Inc |
composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
SG145746A1
(en)
*
|
2003-08-08 |
2008-09-29 |
Fresenius Kabi De Gmbh |
Conjugates of hydroxyalkyl starch and g-csf
|
WO2005014655A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
WO2005014024A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of a polymer and a protein linked by an oxime linking group
|
CA2542179A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
US20050208095A1
(en)
*
|
2003-11-20 |
2005-09-22 |
Angiotech International Ag |
Polymer compositions and methods for their use
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US7842661B2
(en)
|
2003-11-24 |
2010-11-30 |
Novo Nordisk A/S |
Glycopegylated erythropoietin formulations
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
CA2552892C
(en)
|
2004-01-08 |
2014-08-05 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
NZ586034A
(en)
|
2004-02-02 |
2011-10-28 |
Ambrx Inc |
Modified human growth hormone polypeptides and their uses
|
TW200603818A
(en)
*
|
2004-03-11 |
2006-02-01 |
Fresenius Kabi De Gmbh |
Conjugates of hydroxyethyl starch and erythropoietin
|
WO2005092928A1
(en)
*
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
WO2006083260A2
(en)
|
2004-04-28 |
2006-08-10 |
Angiotech Biomaterials Corporation |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
US7632924B2
(en)
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
US20090292110A1
(en)
*
|
2004-07-23 |
2009-11-26 |
Defrees Shawn |
Enzymatic modification of glycopeptides
|
EP1799249A2
(de)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegyliertes interferon alpha
|
CA2581093C
(en)
|
2004-09-17 |
2014-11-18 |
Angiotech Biomaterials Corporation |
Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
|
CA2584157C
(en)
|
2004-10-22 |
2014-10-14 |
Zymogenetics, Inc. |
Anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
CA2584510C
(en)
*
|
2004-10-25 |
2013-05-28 |
Intezyne Technologies, Incorporated |
Heterobifunctional poly(ethylene glycol) and uses thereof
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
CA2594557C
(en)
|
2004-12-22 |
2016-04-26 |
Ambrx, Inc. |
Modified human growth hormone
|
MX2007007732A
(es)
*
|
2004-12-22 |
2007-10-08 |
Kuros Biosurgery Ag |
Hidrogeles peg con grupos funcionales para la reaccion de adicion tipo michael con biofactores incorporados con el factor xiiia.
|
EP1858543B1
(de)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
|
CA2596232A1
(en)
*
|
2005-01-31 |
2006-08-03 |
Effector Cell Institute |
The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment
|
CA2598528A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Fresenius Kabi Deutschland Gmbh |
Production of bioactive glycoproteins from inactive starting material
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US8148123B2
(en)
*
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
MX2007012547A
(es)
|
2005-04-11 |
2008-03-11 |
Savient Pharmaceuticals Inc |
Formas variantes de urato oxidasa y uso de las mismas.
|
US20080159976A1
(en)
*
|
2005-04-11 |
2008-07-03 |
Jacob Hartman |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
CN101194016B
(zh)
|
2005-04-11 |
2012-09-05 |
萨文特医药公司 |
尿酸氧化酶的变体形式及其用途
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2006125452A1
(en)
*
|
2005-05-23 |
2006-11-30 |
Universite De Geneve |
Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
|
US20080255026A1
(en)
*
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
CN102719508A
(zh)
*
|
2005-08-19 |
2012-10-10 |
诺和诺德公司 |
糖基聚乙二醇化的因子vii和因子viia
|
EP1762250A1
(de)
*
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
CN101454461A
(zh)
|
2005-11-16 |
2009-06-10 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
PL2013225T3
(pl)
*
|
2006-04-12 |
2015-06-30 |
Crealta Pharmaceuticals Llc |
Oczyszczanie białek z zastosowaniem kationowego środka powierzchniowo czynnego
|
WO2007127473A2
(en)
|
2006-04-27 |
2007-11-08 |
Intezyne Technologies, Inc. |
Poly (ethylene glycol) containing chemically disparate endgroups
|
RU2008145084A
(ru)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
CN101522707B
(zh)
*
|
2006-08-03 |
2013-08-28 |
莫约斯汀医疗有限公司 |
肌肉生长抑制素拮抗剂
|
ITMI20061624A1
(it)
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
AR063384A1
(es)
*
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
DK2144923T3
(da)
|
2007-04-03 |
2013-05-13 |
Biogenerix Ag |
Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
|
EP2537539B1
(de)
*
|
2007-04-13 |
2019-04-03 |
Kuros Biosurgery AG |
Polymergewebeversiegelungsmittel
|
EP2162540A2
(de)
|
2007-05-22 |
2010-03-17 |
Amgen Inc. |
Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
US7968811B2
(en)
*
|
2007-06-29 |
2011-06-28 |
Harley-Davidson Motor Company Group, Inc. |
Integrated ignition and key switch
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
AU2008326324B9
(en)
|
2007-11-20 |
2012-11-15 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
EP2070951A1
(de)
*
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
|
EP2070950A1
(de)
*
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkylstärkederivate und deren Herstellungsverfahren
|
US9938333B2
(en)
|
2008-02-08 |
2018-04-10 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
ES2963062T3
(es)
|
2008-07-23 |
2024-03-25 |
Ambrx Inc |
Polipéptidos G-CSF bovinos modificados y sus usos
|
CN102131518B
(zh)
*
|
2008-08-25 |
2016-01-20 |
百疗医株式会社 |
包含白介素-11类似物的生物聚合物缀合物
|
BRPI0919403A2
(pt)
|
2008-09-26 |
2017-09-26 |
Ambrx Inc |
polipeptídeos modificados de eritropoetina animal e seus usos
|
NZ592249A
(en)
|
2008-09-26 |
2013-03-28 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
WO2010151823A1
(en)
|
2009-06-25 |
2010-12-29 |
Savient Pharmaceuticals Inc. |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
EP3081233B1
(de)
|
2009-07-27 |
2020-12-23 |
Baxalta GmbH |
Glycopolysialylierung von proteinen ausser blutgerinnungsproteinen
|
ES2856055T3
(es)
*
|
2009-07-27 |
2021-09-27 |
Baxalta GmbH |
Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
CA2791841C
(en)
|
2010-03-05 |
2023-01-03 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
JP2013528374A
(ja)
|
2010-05-10 |
2013-07-11 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
Vla4のポリペプチド阻害剤
|
ES2652508T3
(es)
*
|
2010-08-06 |
2018-02-02 |
Genzyme Corporation |
Composiciones de antagonistas de VEGF y sus usos
|
EP2605789B1
(de)
|
2010-08-17 |
2019-06-05 |
Ambrx, Inc. |
Modifizierte relaxinpolypeptide und ihre verwendungen
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2686340A2
(de)
|
2011-03-16 |
2014-01-22 |
Amgen Inc. |
Hochwirksame und selektive inhibitoren von nav1.3 nav1.7
|
AU2012280474A1
(en)
|
2011-07-01 |
2014-01-16 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
US9738724B2
(en)
|
2012-06-08 |
2017-08-22 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP2863955B1
(de)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
SI3584255T1
(sl)
|
2012-08-31 |
2022-05-31 |
Sutro Biopharma, Inc |
Modificirane aminokisline, ki vsebujejo azido skupino
|
EP2935311B1
(de)
|
2012-12-20 |
2021-03-31 |
Amgen Inc. |
Apj-rezeptoragonisten und verwendungen davon
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
ES2658039T3
(es)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015191781A2
(en)
|
2014-06-10 |
2015-12-17 |
Amgen Inc. |
Apelin polypeptides
|
KR20240024362A
(ko)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
MX2019008449A
(es)
|
2017-02-08 |
2019-09-09 |
Bristol Myers Squibb Co |
Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
|
SG11202102427XA
(en)
|
2018-09-11 |
2021-04-29 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and their uses
|
EP3867265A1
(de)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
|
JP2022520792A
(ja)
|
2019-02-12 |
2022-04-01 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
IL296099A
(en)
|
2020-03-11 |
2022-11-01 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and methods of using them
|
WO2022040596A1
(en)
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|